James G Carlucci1, Meridith Blevins Peratikos, Aaron M Kipp, Mary L Lindegren, Quy T Du, Lorna Renner, Gary Reubenson, John Ssali, Marcel Yotebieng, Anna M Mandalakas, Mary-Ann Davies, Marie Ballif, Lukas Fenner, April C Pettit. 1. *Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Abstract
INTRODUCTION: Management of tuberculosis (TB) is challenging in HIV/TB-coinfected children. The World Health Organization recommends nucleic acid amplification tests for TB diagnosis, a 4-drug regimen including ethambutol during intensive phase (IP) of treatment, and initiation of antiretroviral therapy (ART) within 8 weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic modality, IP regimen, and ART status. METHODS: We conducted a retrospective cohort study among HIV/TB-coinfected children enrolled at the International Epidemiology Databases to Evaluate AIDS treatment sites from 2012 to 2014. We modeled TB outcome using multivariable logistic regression including diagnostic modality, IP regimen, and ART status. RESULTS: Among the 386 HIV-infected children diagnosed with TB, 20% had microbiologic confirmation of TB, and 20% had unfavorable TB outcomes. During IP, 78% were treated with a 4-drug regimen. Thirty-one percent were receiving ART at the time of TB diagnosis, and 32% were started on ART within 8 weeks of TB diagnosis. Incidence of ART initiation within 8 weeks of TB diagnosis was higher for those with favorable TB outcomes (64%) compared with those with unfavorable outcomes (40%) (P = 0.04). Neither diagnostic modality (odds ratio 1.77; 95% confidence interval: 0.86 to 3.65) nor IP regimen (odds ratio 0.88; 95% confidence interval: 0.43 to 1.80) was associated with TB outcome. DISCUSSION: In this multinational study of HIV/TB-coinfected children, many were not managed as per World Health Organization guidelines. Children with favorable TB outcomes initiated ART sooner than children with unfavorable outcomes. These findings highlight the importance of early ART for children with HIV/TB coinfection, and reinforce the need for implementation research to improve pediatric TB management.
INTRODUCTION: Management of tuberculosis (TB) is challenging in HIV/TB-coinfectedchildren. The World Health Organization recommends nucleic acid amplification tests for TB diagnosis, a 4-drug regimen including ethambutol during intensive phase (IP) of treatment, and initiation of antiretroviral therapy (ART) within 8 weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic modality, IP regimen, and ART status. METHODS: We conducted a retrospective cohort study among HIV/TB-coinfectedchildren enrolled at the International Epidemiology Databases to Evaluate AIDS treatment sites from 2012 to 2014. We modeled TB outcome using multivariable logistic regression including diagnostic modality, IP regimen, and ART status. RESULTS: Among the 386 HIV-infectedchildren diagnosed with TB, 20% had microbiologic confirmation of TB, and 20% had unfavorable TB outcomes. During IP, 78% were treated with a 4-drug regimen. Thirty-one percent were receiving ART at the time of TB diagnosis, and 32% were started on ART within 8 weeks of TB diagnosis. Incidence of ART initiation within 8 weeks of TB diagnosis was higher for those with favorable TB outcomes (64%) compared with those with unfavorable outcomes (40%) (P = 0.04). Neither diagnostic modality (odds ratio 1.77; 95% confidence interval: 0.86 to 3.65) nor IP regimen (odds ratio 0.88; 95% confidence interval: 0.43 to 1.80) was associated with TB outcome. DISCUSSION: In this multinational study of HIV/TB-coinfectedchildren, many were not managed as per World Health Organization guidelines. Children with favorable TB outcomes initiated ART sooner than children with unfavorable outcomes. These findings highlight the importance of early ART for children with HIV/TB coinfection, and reinforce the need for implementation research to improve pediatric TB management.
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: R M Hicks; N Padayatchi; N S Shah; A Wolf; L Werner; V B Sunkari; M R O'Donnell Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: Solomon M Abay; Kebede Deribe; Ayalu A Reda; Sibhatu Biadgilign; Daniel Datiko; Tigist Assefa; Maja Todd; Amare Deribew Journal: J Int Assoc Provid AIDS Care Date: 2015-08-19
Authors: Marie Ballif; Lorna Renner; Jean Claude Dusingize; Valeriane Leroy; Samuel Ayaya; Kara Wools-Kaloustian; Claudia P Cortes; Catherine C McGowan; Claire Graber; Anna M Mandalakas; Lynne M Mofenson; Matthias Egger; Ketut Dewi Kumara Wati; Revathy Nallusamy; Gary Reubenson; Mary-Ann Davies; Lukas Fenner Journal: J Pediatric Infect Dis Soc Date: 2014-03-28 Impact factor: 3.164
Authors: Michelle Earley; Joconiah Chirenda; Alexandra Highet; Hilda A Mujuru; Zhenhua Yang Journal: Am J Trop Med Hyg Date: 2018-07-12 Impact factor: 2.345
Authors: Frédérique Chammartin; Cam Ha Dao Ostinelli; Kathryn Anastos; Antoine Jaquet; Ellen Brazier; Steven Brown; Francois Dabis; Mary-Ann Davies; Stephany N Duda; Karen Malateste; Denis Nash; Kara Wools-Kaloustian; Per M von Groote; Matthias Egger Journal: BMJ Open Date: 2020-05-15 Impact factor: 2.692
Authors: Kathrin Zürcher; Marie Ballif; Sasisopin Kiertiburanakul; Henri Chenal; Marcel Yotebieng; Beatriz Grinsztejn; Denna Michael; Timothy R Sterling; Kapella M Ngonyani; Anna M Mandalakas; Matthias Egger; April C Pettit; Lukas Fenner Journal: J Int AIDS Soc Date: 2019-09 Impact factor: 5.396
Authors: Anna M Mandalakas; Alexander W Kay; Jason M Bacha; Tara Devezin; Rachel Golin; Katherine R Simon; Dilsher Dhillon; Sandile Dlamini; Andrew DiNardo; Mogo Matshaba; Jill Sanders; Lineo Thahane; Pauline M Amuge; Saeed Ahmed; Moorine P Sekadde; Neway G Fida; Bhekumusa Lukhele; Nodumo Chidah; David Damba; Joseph Mhango; Moses Chodota; Makhorong Matsoso; Angelina Kayabu; Richard S Wanless; Gordon E Schutze Journal: Emerg Infect Dis Date: 2020-12 Impact factor: 6.883